- Home
- RIGL vs REFI Comparison
RIGL vs REFI Comparison
Compare RIGL & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | REFI |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 255.6M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RIGL | REFI |
|---|---|---|
| Price | $40.96 | $13.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $43.20 | $20.00 |
| AVG Volume (30 Days) | ★ 593.7K | 99.6K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 15.29% |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | 1.69 |
| Revenue | ★ $282,076,000.00 | $54,287,847.00 |
| Revenue This Year | $65.53 | $13.78 |
| Revenue Next Year | $0.22 | $4.07 |
| P/E Ratio | ★ $6.58 | $7.95 |
| Revenue Growth | ★ 79.13 | N/A |
| 52 Week Low | $14.63 | $11.85 |
| 52 Week High | $52.24 | $16.29 |
Technical Indicators
Market Signals| Indicator | RIGL | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 66.72 |
| Support Level | $39.60 | $12.60 |
| Resistance Level | $43.58 | $12.92 |
| Average True Range (ATR) | 3.20 | 0.25 |
| MACD | -1.27 | 0.10 |
| Stochastic Oscillator | 11.83 | 97.22 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.